McKesson Corporation: EPS $11.68 vs $10.72 expected; revenue $111.0B vs $109.9B
Key Facts
Q2 FY2027 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 11.68 | 10.72 | +9.0% | 9.86 |
| Revenue (USD bn) | 110.96 | 109.90 | +1.0% | 103.15 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Q2 FY2027 | 11.68 | 10.72 | +9.0% | 110.96 | 109.90 | +1.0% |
| Aug 5, 2026 | Q1 FY2027 | 9.93 | 9.56 | +3.9% | 105.38 | 103.88 | +1.4% |
| May 7, 2026 | Q4 FY2026 | 11.69 | 11.56 | +1.1% | 96.30 | 101.35 | −5.0% |
| Feb 4, 2026 | Q3 FY2026 | 9.34 | 9.17 | +1.9% | 106.16 | 105.80 | +0.3% |
| Nov 5, 2025 | Q2 FY2026 | 9.86 | 9.03 | +9.2% | 103.15 | 104.14 | −0.9% |
| Aug 6, 2025 | Q1 FY2026 | 8.26 | 8.14 | +1.5% | 97.83 | 96.18 | +1.7% |
| May 8, 2025 | Q4 FY2025 | 10.12 | 9.83 | +3.0% | 90.82 | 94.30 | −3.7% |
| Feb 5, 2025 | Q3 FY2025 | 8.03 | 8.60 | −6.6% | 95.29 | 96.05 | −0.8% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
McKesson Corporation results: EPS $11.68 vs $10.72 expected; revenue $111.0B vs $109.9B. The results cover the company's Q2 FY2027. EPS came in above analysts' estimate by 9.0%; revenue above the estimate by 1.0%.
Revenue was up 7.6% from $103.2 billion a year earlier (Q2 FY2026). EPS was up 18.5% from $9.86 a year earlier. On its record, EPS topped analysts' estimates in 6 of 7 earlier comparable reports.
What the results mean
According to the company's results release, management raised its financial outlook.
McKesson Corporation’s results reflect strong demand for specialty pharmaceutical distribution and provider services, supported by increased prescription volumes and growth in oncology and multispecialty operations. These drivers supported operating performance despite reduced contributions from branded pharmaceuticals. Management emphasized strength in the core businesses and disciplined execution and investment.
Demand for solutions that help patients access medications supported growth in prescription technology services. Meanwhile, Medical-Surgical Solutions profitability declined because of the product mix in ambulatory care, despite revenue growth. This illustrates how the composition of products and services affects profitability alongside business volume.
The acquisition of Precision Medicine Group and the agreement to invest in Option Care Health reflect the company’s push to expand specialty therapy, oncology, and community care services. The acquisition has closed, while the proposed investment remains subject to approvals and closing conditions, making execution and financial discipline central to understanding these steps.
What to watch on the earnings call: Durability of demand for specialty pharmaceuticals and medication access solutions, reasons for reduced branded pharmaceutical contributions, the effect of product mix on Medical-Surgical Solutions profitability, integration plans for Precision Medicine Group, progress toward approvals for the Option Care Health investment, and the balance between expansion and spending discipline.
For the full analysis of McKesson Corporation stock — valuation, scores and financial statements — see the stock page linked with this story.